title: Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.
abstract: Individuals vaccinated against smallpox maintain substantial antiviral antibody responses for many years after vaccination. In this study, we examined the ability of antiviral antibodies from 104 unique serum samples to neutralize the two infectious forms of vaccinia virus, intracellular mature virus (IMV) and extracellular enveloped virus (EEV). While we found direct correlations between antiviral antibody titers and the ability to neutralize IMV and EEV, correlation with EEV neutralization was weaker. To determine factors that may influence more varied EEV neutralization within a vaccinated population, we asked the following questions. (1) Does vaccinia virus-neutralizing ability remain constant over time? (2) Do multiple vaccinations boost IMV and EEV neutralization activity? We found that serum from vaccinated individuals retained ability to neutralize EEV for a relatively long time, but there was a significant drop in EEV neutralization ability in the third decade after vaccination. While all vaccinees maintained some ability to neutralize IMV, a number of individuals lost the capacity to neutralize EEV. Interestingly, the ability to neutralize either virus form was not altered by the number of vaccinations received. Since it is likely that neutralizing antibodies against both IMV and EEV are required for maximal protective immunity, a loss of anti-EEV-neutralizing ability may warrant the revaccination of individuals who have been vaccinated >20 years ago, should widespread pre-event smallpox vaccination be instituted.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, Philadelphia, PA 19104-6073, USA.
authors.forename: Kendra M
authors.initials: KM
authors.lastname: Viner
authors.forename: Stuart N
authors.initials: SN
authors.lastname: Isaacs
mesh_terms: D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology*; D000918:Antibody Specificity; D006801:Humans; D009500:Neutralization Tests; D012899:Smallpox / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000008:administration & dosage* / Q000276:immunology; D013997:Time Factors; D014616:Vaccinia virus / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D000914:Antibodies, Viral; D012900:Smallpox Vaccine